Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ImmunoCellular Therapeutics Announces Issuance of Key Patent for Cancer Vaccine Target

Published: Friday, May 17, 2013
Last Updated: Friday, May 17, 2013
Bookmark and Share
The US Patent and Trademark Office (USPTO) has issued a patent covering methods of use of interleukin 13-receptor alpha 2 protein (IL-13Ra2) in cancer immunotherapy.

IL-13 is an immune regulatory cytokine and IL-13Rα2 is highly and specifically expressed in glioblastoma, ovarian and other solid tumors, but not in normal tissue. IL-13Rα2 is an important target of ImmunoCellular’s lead product candidate, ICT-107, a dendritic cell vaccine directed against glioblastoma antigens and cancer stem cells, as well as ICT-140, a dendritic cell vaccine to treat ovarian cancer.

“We believe that this issued patent will complement and extend the broad intellectual property protection we have established for two of our company’s key assets, ICT-107 and ICT-140, and represents a valuable addition to our patent estate,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “IL-13Rα2 is a tumor-associated antigen present in the majority of brain cancers, and we believe that using an immunotherapeutic vaccine that targets this and other specific antigens as well as cancer stem cells to stimulate an immune response represents a promising anticancer approach.”

The IL-13Rα2 patent was issued to The Penn State Research Foundation, the technology transfer agent for The Pennsylvania State University, and is licensed to Targepeutics, Inc. ImmunoCellular is a sub-licensee of the patent.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine
Key patent application covers ICT-121, an immunotherapeutic vaccine targeting CD133, an important cancer stem cell marker that is commonly overexpressed on a broad range of solid tumors.
Tuesday, March 05, 2013
ImmunoCellular Therapeutics’ Investigational New Drug Application for ICT-140 Allowed by the FDA
Investigational new drug (IND) application for ICT-140 paves the way for conducting a clinical trial.
Wednesday, January 30, 2013
ImmunoCellular Therapeutics Enters into Research and License Option Agreement with Roche Group
The Company will license to Roche the rights to investigate regarding its ICT-69 antibody in the treatment of multiple myeloma and ovarian cancer.
Friday, September 11, 2009
ImmunoCellular Therapeutics’ Cancer Vaccine Demonstrates Immune Response against Brain Cancer in Clinical Trial
Company presents promising clinical data from a Phase I trial evaluating dendritic cell-based cancer vaccine for the treatment of glioblastoma.
Friday, December 26, 2008
ImmunoCellular Therapeutics Announces Completion of Proof-of-Principle Studies
The study demonstrates efficacy of Company’s cancer stem cell vaccine in preclinical model.
Wednesday, May 28, 2008
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!